UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

A recap of the Microbiome & Probiotics Series: Europe

The Microbiome & Probiotics Series: Europe is one of the highlights of our calendar year. Kristin Neumann, author & founder of MyMicrobiome was one of our speakers on the cosmeceuticals track and was kind enough to write the following recap of the event, for people who weren’t able to attend this year. You can read the original article here.

Read More

The benefits of network-driven drug discovery

e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.

Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.

Read More

Controlling the fate of cancer cells with SF3B1 modulators

Andrew Cook has worked in the pharmaceutical industry for over 20 years. Throughout his career, he has endeavoured to do things differently, a little out of the ordinary, leading him to his work at H3 Biomedicine on splice modulators. “Part of the reason it attracted me” he says, “is it’s so different. It’s a natural product-based drug discovery effort, and I had never done that before”.

Read More

Microbial solutions to improve crop growth, crop protection, and crop yield

Gregory Maloney, Senior Scientist at Novozymes BioAg will be hosting a roundtable discussion at the Partnerships in Biocontrol, Biostimulants & Microbiome Congress: USA on navigating the regulatory landscape of biological product development. We spoke to him ahead of the congress about his work.

Read More

Presentation slides from the 6th Microbiome R&D & Business Collaboration Forum

Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides available from Finn Terge Hegge, Angela Sessitsch, Evelina Munukka and Jonathan de Jonge.

Read More

A new kind of pheromone to control agricultural pests

Karl Cameron Schiller is co-founder of Pheronym, a Davis-based agriculture biotech start-up using a new kind of pheromone from microscopic roundworms called nematodes to control agricultural pests. We asked him about his work.

Read More

Going back to biology and the hype of AI in pharma

With a background in pharmacology, toxicology, molecular cell biology and genetics, Rangaprasad Sarangarajan joined BERG Health in 2010 as head of R&D.

In the initial years of the company, he aided in the conception, design, and implementation of the paradigm of looking at human biology, use of technology to generate molecular signatures, and the use of artificial intelligence-based analytics for understanding the complexity of biology, identifying of targets, and developing of drugs, and its utility in clinical development.

Read More

Navigating the regulatory landscape for agricultural products

Terry Stone has worked in agricultural products for almost 30 years and has experience in both research and regulatory affairs. He is currently Vice President of Regulatory Affairs and Sustainability Programs for Agrinos, where he works with industry associations in the US and the EU to develop a regulatory framework for plant biostimulants. We spoke to him about his work.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive